Insilico Medicine has expanded its collaboration with China Medical System Holdings (CMS) to enhance AI-driven drug discovery for central nervous system (CNS) conditions. This partnership builds on a previous agreement established three months prior.
The new collaboration focuses on a unique mechanism of action discovered through Insilico's PandaOmics platform, which is integral to its Pharma.ai suite that includes tools for molecule generation and trial outcome predictions. Under this deal, Insilico stands to gain up to RMB 1.2 billion in milestone payments and royalties.
Both companies aim to leverage Insilico's generative AI capabilities alongside CMS's established infrastructure in clinical development and regulatory processes in China. CMS, listed in Hong Kong and Singapore, emphasizes innovation in commercialization and lifecycle management for pharmaceuticals.
Leaders from both organizations expressed confidence in the partnership’s potential, noting the effective collaboration thus far. This agreement illustrates the increasing significance of generative AI in identifying targets for complex CNS indications, as pharmaceutical companies strive to expedite the transition from target discovery to clinical application.